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Abstract
Objective: Clopidogrel has become the standard of care to prevent thrombotic complications following cardiological interventions, in
particular intracoronary stenting. In addition, patients with aspirin intolerance and those with carotid and peripheral vascular disease are also
increasingly treated with clopidogrel. Platelet inhibition may become a concern for hemostasis in patients treated with clopidogrel who need
emergency and undelayed surgery. Methods: We prospectively analyzed the intra- and postoperative outcome of 505 consecutive patients
who underwent isolated CABG and compared two groups: those with clopidogrel exposure until 72 h prior to surgery ðn ¼ 136Þ with those
without exposition to clopidogrel ðn ¼ 369Þ: Patients undergoing emergency surgery because of failed PTCA and cardiogenic shock,
associated valvular surgery, redo-CABG, and those with additional platelet IIb/IIIa receptor inhibitor exposure were excluded. Patients who
received aspirin and/or heparin treatment prior to surgery were not excluded. Results: Patients who received clopidogrel had a higher
prevalence of angina class III or IV (67 vs 39%, P , 0:01), received more often revascularization within 48 h (41 vs 14%, P ¼ 0:02), and had
received more frequently stenting (57 vs 13%). Chest tube drainage was significantly increased during the first 24 h following CABG in the
group of patients who had clopidogrel treatment (1485 vs 780 ml, P ¼ 0:003) These patients also required more transfusion of platelets and
fresh frozen plasma. Overall re-exploration rate because of bleeding was significantly higher in the clopidogrel group (5.9 vs 1.2%,
P , 0:01). Platelets transfused before chest closure had a beneficial effect on preservation of the hemostasis. Conclusions: Clopidogrel
exposure 3 days or less prior to CABG surgery significantly increases the risk of postoperative bleeding, the need for perioperative
transfusion and the incidence of re-exploration. Surgery should be performed using standard heparinization and anti-fibrinolytic strategies
but aggressive correction of platelets dysfunction is required before chest closure.
q 2004 Elsevier B.V. All rights reserved.
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1. Introduction
During the last decade, a multitude of antiplatelets and
anticoagulatory agents have been used in patients with
coronary artery disease, especially in the periprocedural
period of PTCA alone or following intracoronary stenting.
The majority of these agents, including thienopyridines,
particularly clopidogrel and ticlopidine, and glycoproteines
IIb/IIIa inhibitors has been demonstrated to have beneficial
effects on the outcome of intracoronary interventional
procedures [1–3]. Moreover, ticlopidine and clopidogrel,
which act on the cyclic adenosine monophosphate pathway
to irreversibly inhibit platelets, are increasingly popular
substitutes for and/or complementary to aspirin in the
management of thromboembolic and occlusive arterial
disease.
Clopidogrel has emerged as the standard of care to prevent
stent thrombosis in interventional cardiology. Patients with
acute coronary syndrome and more recently those with
carotid and peripheral vascular disease are also increasingly
treated with clopidogrel [4–6]. Clopidogrel has the follow-
ing advantages over the other thienopyridine ticlopidine:
(1) the onset of action is shorter, (2) the time to reach a steady
state following a loading dose of 300 mg is shorter and (3) the
incidence of side effects is significantly lower.
The cause of early postoperative bleeding following on-
pump CABG may be multifactorial; insufficient surgical
European Journal of Cardio-thoracic Surgery 26 (2004) 96–101
www.elsevier.com/locate/ejcts
1010-7940/$ - see front matter q 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.ejcts.2004.03.030
q Presented at the joint 17th Annual Meeting of the European Association
for Cardio-thoracic Surgery and the 11th Annual Meeting of the European
Society of Thoracic Surgeons, Vienna, Austria, October 12–15 2003.
* Corresponding author. Tel.: þ41-31-632-2375; fax: þ41-31-632-4443.
E-mail address: thierry.carrel@insel.ch (T. Carrel).s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
1
6
0
1
2
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
hemostasis, disorders of the coagulation system due to
hemodilution, platelets dysfunction as well as negative
effects of the cardiopulmonary bypass circuit are the most
common causes for impaired hemostasis [7,8]. Platelet
inhibition by clopidogrel may become crucial for hemo-
stasis in patients who need emergency surgery. On the other
hand, the development of new strategies (for instance
OPCAB, miniaturization of CPB circuits, preoperative
blood donation, acute normovolemic hemodilution) and
some pharmacologic interventions (erythropoietine) have
reduced the need for allogeneic blood transfusion and the
rate of re-exploration for bleeding [8].
Aim of this study was to analyze the influence of
Clopidogrel treatment on postoperative bleeding and
transfusion requirements as well as on overall outcome in
patients who received isolated myocardial revascularization
in our institution.
2. Methods
We prospectively analyzed the early postoperative
outcome of 505 consecutive patients who underwent
primary isolated CABG and compared two groups of
patients: those who received Clopidogrel within 72 h of
surgery ðn ¼ 136Þ to those who did not receive Clopidogrel
ðn ¼ 369Þ: Patients undergoing emergency surgery because
of failed PTCA and cardiogenic shock, patients scheduled
for CABG combined to valvular surgery, redo-CABG, and
those who received platelet IIb/IIIa receptor inhibitors were
excluded. The main indications for Clopidogrel treatment
are listed on Table 1. In five percent of the patients, no clear-
cut indication for clopidogrel administration could be found.
The main demographic characteristics of the patients, the
operative strategy as well as the main perioperative and
postoperative complications were recorded. The use of any
additional antiplatelet medication other than Clopidogrel or
oral anticoagulation treatment in the last 7 days prior to
surgery was recorded. Length of stay on the intensive care
unit and total hospitalization were also recorded.
Low-dose aprotinin was administrated in the pump prime
(2 mio KIU) in all patients operated with the aid of
cardiopulmonary bypass. In these patients, heparin
(300 IU/kg) was administred before cannulation to reach a
ACT value higher than 480 s. Heparin reversal was achieved
with 1:1 protamine. In patients who underwent beating heart
CABG (OPCAB), 2 mio KIU aprotinin were administred as a
loading dose during induction of the anaesthesia and a
continuous infusion of 500,000 KIU/h during the procedure.
Heparin (100 IU/kg) was given immediately before flow
interruption in the 1st target coronary vessel to reach an ACT
value of approximately 250 s. Heparin reversal was
performed with half of the protamin dose.
During extracorporeal perfusion, transfusion of red blood
cells was performed when hematocrite value decreased
under 0.18. Postoperative transfusion of packed red blood
cells was found to be indicated when hematocrite value was
lower than 0.24. Platelets were transfused when the total
count was lower than 80,000 and there was a increasing
and/or prolonged tendency of postoperative bleeding. The
timing of platelet transfusion (before chest closure or later
on the intensive care unit) was examined. Surgical re-
exploration was found to be indicated when bleeding
exceeded 400 ml during the first hour or when it was more
than 300 ml/h during the next 3 h despite normalized ACT
and global coagulation status.
Preoperative hematocrite and the lowest intraoperative
hematocrite value were recorded. Total chest tube drainage
during the first 24 h, the incidence of re-exploration and the
early outcome (mortality, incidence of major complications,
duration of mechanical ventilation, stay in the intensive care
unit and total hospitalization time) were assessed. Finally
the exposure to blood products was analyzed.
2.1. Statistical analysis
Main clinical characteristics (age, gender, cardiovascular
risk factors, functional class, Euroscore value) of patients
with and without clopidogrel were recorded; an additional
analysis was performed to compare on-pump patients and
OPCAB patients separately. Fisher’s exact or chi-square test
was used to compare differences in proportions. Continuous
variables are expressed as mean ^ SD and were compared
with parametric (Student’s t-test) or nonparametric
(Wilcoxon test) based on the distribution of variables.
A two-tailed P , 0:05 was considered to be statistically
significant. Multivariate analysis with a logistic regression
was performed to determine whether preoperative clopido-
grel was an independent risk factor for re-exploration,
increased drainage output through the chest tubes during the
first 24 h and the need for transfusion of packed red cells and
platelets.
Statistical analysis was performed with SPSS software
version.
3. Results
There was no significant difference in the main
demographic characteristics of the patients between the 2
groups with or without Clopidogrel; within the subset of
Table 1
Main indications for clopidogrel treatment ðn ¼ 136Þ
Prior percutaneous coronary intervention 92 (67.6%)
Unstable angina 69 (58%)
Acute myocardial infarction 46 (33.8%)
Intolerance of aspirin 6 (4.4%)
Cerebrovascular disease 11 (8%)
Peripheral vascular disease (^PTA) 16 (11.7%)
Unclear indication 13 (9.5%)
Several indications in the same patient possible.
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OPCAB-patients, there was also no difference in demo-
graphic factors between those who had received Clopido-
grel and those who did not (Table 2). Additional exposure to
salicylic acid and to intravenous heparin was comparable
between the different groups. Patients who received
Clopidogrel had a higher prevalence of acute coronary
syndrome (73 versus 16%, P , 0:001), angina functional
class III or IV (67 vs 39%, P , 0:01), surgical revascular-
ization within 48 h following cardiac catheterism (41 vs
14%, P ¼ 0:02), and preoperative stenting (57 vs 13%,
P , 0:001) (Table 3).
The intraoperative technical details (Table 4) as well as
the intra- and perioperative anticoagulation management
were comparable between the 2 groups. However some
differences existed depending on the operative technique
(OPCAB or on-pump). As expected, patients given
Clopidogrel had a higher mean chest tube drainage 24 h
after the procedure (1485 vs 780 ml, P ¼ 0:003), but there
was a trend to decreased bleeding when platelets were
transfused before chest closure as compared to transfusion
once the operation had be terminated Table 5). Patients with
Clopidogrel required more transfusion of platelets and fresh
frozen plasma (Table 6). Thirty day-mortality was similar in
both groups (Clopidogrel or not 1.4 vs 0.8%) and for both
operative techniques (on-pump and OPCAB, 0.9 vs 1.4%)
and was not dependent from urgency of revascularization.
Overall re-exploration rate because of postoperative bleed-
ing was significantly higher in the Copidogrel group (5.9 vs
1.2%, P , 0:01). However, clinical outcome was compar-
able within both groups (Table 7).
4. Discussion
It is increasingly common for patients who need CABG
surgery to be undergoing pharmacological alteration of
hemostasis, because anti-platelet drugs have demonstrated
considerable success in the treatment of acute coronary
syndrome, including unstable angina and acute myocardial
infarction and following percutaneous coronary interven-
tions [9,10]. Acquired platelet dysfunction is one of the
most commonly encountered hemostatic defects among
patients undergoing surgical procedures, and drug-induced
platelet dysfunction may turn out to be a major concern
while hemostasis is performed. The main factors that may
affect bleeding and transfusion requirements in these
patients are: presence of risk factors for bleeding, proper
transfusion practices, conserving or increasing the red cell
mass, as well as appropriate heparin dosing and protamine
reversal [11]. In particular, excess protamine should be
avoided in these patients because of the adverse effects on
coagulation factors and platelets [12].
Differentiating between postoperative bleeding due to
coagulopathy and a surgical reason that should be corrected
with re-exploration is not always straightforward in the
early postoperative course, and this may additionally
complicated by preoperative clopidogrel administration.
There is only scarce literature about effects of Clopidogrel
on bleeding after coronary artery bypass surgery, but in all
Table 2
Demographic data
Clopidogrel No Clopidogrel P-value
Number of patients 136 369
Gender m:f 104:32 286:83 ns
Age (years) 66 ^ 10.6 68 ^ 8.4 ns
Body mass index 27.6 ^ 2.9 26.9 ^ 4.1 ns
Renal failure
(creatinin .150 mmol/l)
11 (8%) 37 (10%) ns
Table 3
Cardiovascular history
Clopidogrel
ðn ¼ 136Þ
No clopidogrel
ðn ¼ 369Þ
P-value
Prior myocardial infarction
Angina functional
class III or IV
67% 39% ,0.01
Ejection fraction (%) 44 ^ 7.5 49 ^ 11 ns
Prior PTCA 19% 11% ns
Prior PTCA þ stenting 57% 13% , 0.001
Surgery within 48 h 41% 14% 0.07
Mean Interval
PCI—surgery (d)
9 ^ 6.5 17 ^ 9 0.097
Table 4
Intraoperative data
Clopidogrel
ðn ¼ 136Þ
No clopidogrel
ðn ¼ 369Þ
P-value
On-pump 114/136 (83.8%) 320/369 (86.7%) ns
Pump-assisted
beating hearta
25/114 (21.9%) 29/320 (9%) 0.04
OPCAB 22/136 (16.2%) 49/369 (13.3%) ns
Number of coronary
anastomoses
3.6 ^ 0.3 3.8 ^ 0.5 ns
Bypass time (min) 67 ^ 15 62 ^ 11 ns
Ischemia time (min) 43 ^ 13 46 ^ 17 ns
a Minimal ECC system, on-pump beating heart, centrifugal pump.
Table 5
Chest tube output and re-exploration
Clopidogrel No clopidogrel P-value
Overall CABG ðn ¼ 136Þ ðn ¼ 369Þ
Drainage (ml/24 h) 1485 ^ 310 780 ^ 105 0.003
Re-exploration 8 (5.9%) 5 (1.2%) ,0.01
On pump ðn ¼ 114Þ ðn ¼ 320Þ
Drainage (ml/24 h) 1550 ^ 300 850 ^ 140 0.025
Re-exploration 7 4
OPCAB ðn ¼ 22Þ ðn ¼ 49Þ
Drainage (ml/24 h) 1250 ^ 430 660 ^ 170 0.04
Re-exploration 1 1
Diffuse bleeding 7 3
Surgical bleeding 1 2
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reports available yet, it has been demonstrated that
Clopidogrel-treated patients have increased rates of bleed-
ing, transfusion of blood products and re-exploration for
bleeding [9,13–15]. In a retrospective analysis including
128 aspirin-treated patients who received bilateral internal
thoracic artery, 64 were additionally on Clopidogrel and 64
not. Both groups were comparable regarding demographics
and intraoperative variables. Chest tube output was higher
in the Clopidogrel group and was responsible for a higher
rate of re-exploration 7.8 versus 0%. The need for
transfusion of blood products was higher in Clopidogrel-
treated patients but the stay on the intensive care station was
not prolonged by these events [13].
Yende and Wunderlink reported their experience with
247 patients, out of which 51 received preoperative
Clopidogrel. In this prospective observational cohort study
designed to detect complications following CABG surgery,
primary and secondary end points were need for re-
exploration because of bleeding, need for transfusion of
blood products and chest tube output respectively. Unfortu-
nately patients who received CABG combined to valve
surgery were not excluded from this observation. Patients
who received preoperative Clopidogrel (a large majority
had also received aspirin and 45% intravenous heparin) had
a higher incidence of re-exploration for bleeding and an
increased need for packed red blood cells and cryoprecipi-
tate transfusion. A large proportion of patients required
urgent surgery (71%) whereas only 20% were operated on
an elective basis [14].
Hongo and co-authors prospectively compared 224
patients undergoing non-emergent CABG and examined
the postoperative outcome of those with and those without
Clopidogrel exposition. The Clopidogrel group had a higher
chest tube output and more transfusion of red blood cells.
The rate of re-exploration because of bleeding was 10-fold
higher in the Clopidogrel group, inducing thereby less
extubation within 8 h and a trend towards less hospital
discharge within 5 days [15].The role of preoperative
Clopidogrel on postoperative outcome in patients under-
going OPCAB surgery is still not elucidated [16].
In cardiopulmonary bypass, in which platelet dysfunc-
tion is extremely common, the bleeding time has never been
shown to have predictive value either preoperatively or
postoperatively. However, considerable progress has been
made in the clinical assessment of platelet function.
Thromboelastography (TEG) for instance has gained
popularity in the perioperative setting; it is used to test
clot strengh over time through examination of the elastic
shear modulus. Thromboelastography is now understood to
test the interaction between fibrin and GP IIb/IIIa. Work
with abciximab has shown a direct dose-dependent relation
between drug and maximum amplitude during TEG. Some
publications have shown it to be a useful predictor of
abnormal postoperative bleeding after cardiac surgery [17].
TEG may be also be a useful tool to guide platelet
transfusion. We have recently introduced TEG as a routine
intraoperative examination but data were not available for
the present trial.
This prospective observational study is limited by the
fact that some preoperative characteristics, especially the
rate of unstable angina and incidence of PCI prior to surgery
were not similar in both groups. Furthermore, neither
surgeons nor anesthesiologists were blinded to antiplatelet
treatment received in the immediate preoperative period,
which means that there was a potential for bias. However an
usual perioperative management was applied in all patients.
Despite the fact that a multivariate analysis was performed,
the influence of intraoperative factors such as technique of
operation (on-pump or OPCAB), type of bypass grafts,
duration of CPB and cross-clamp time, could not be
elucidated. Peri- and postoperative substitution of either
fresh frozen plasma and platelets was based on coagulation
parameters (platelets ,80,000/ml, ACT 10% or more than
baseline, pathologic INR, thrombin time and/or bleeding
time). In case of complete absence of clotting following
adequate reversal of heparin, platelets concentrates were
transfused before closure of the chest.
The management of patients scheduled for CABG who
are on Clopidogrel treatment is controversial. Some trials
suggest that these patients should have surgery delayed until
the platelet function recovers but the optimal duration of this
delay needs further evaluation. In the CURE trial, patients
that interrupted Clopidogrel treatment within 5 days prior to
CABG had a trend towards more bleeding than those
patients in the control placebo group [18]. The drug
Table 6
Transfusion data
Clopidogrel
ðn ¼ 136Þ
No clopidogrel
ðn ¼ 369Þ
P-value
Transfusion
Packed red cells (units) 4.6 ^ 2.3 1.5 ^ 2.2 0.027
Fresh frozen plasma (units) 0.9 ^ 1.4 0.3 ^ 0.9 ns
Platelets (units) 2.6 ^ 1.1 0.2 ^ 0.6 0.001
Blood product exposure
Red blood cells 92% 47% ,0.001
Fresh frozen plasma 42% 13% 0.003
Platelets 71% 9% ,0.001
Table 7
Clinical outcome
Clopidogrel
ðn ¼ 136Þ
No clopidogrel
ðn ¼ 369Þ
P-value
Mortality 1.4% (2/136) 0.8% (3/369) ns
Low cardiac output 8.1% 3.9% 0.03
Perioperative myocardial
infarction
4.3% 3.1% ns
Intubation longer than 12 h 59% 27% 0.08
Mean ICU stay (d) 1.9 ^ 1.3 1.1 ^ 0.7 ns
Mean hospitalization time (d) 9.6 ^ 2.1 7.9 ^ 2.0 ns
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manufacturer recommends that clopidogrel should be
discontinued for 7 days prior to elective coronary surgery.
In all other cases, the risk of bleeding must be weighted
against the risks of delaying the surgery (unstable angina,
myocardial infarction, hemodynamic compromise) [19]. In
our experience, Clopidogrel exposure within 3 days prior to
CABG surgery significantly increases the risk of post-
operative bleeding, the need for perioperative transfusion
and surgical re-exploration. Considering the fact that a
majority of patients receiving Clopidogrel are higher-risk
patients than those who do not, the overall outcome
(mortality and major cardiac or neurologic morbidity) is
still very acceptable. This experience does not justify to
delay the surgical revascularization in all patients treated
with Clopidogrel [20–22].
Surgery should be performed using standard anticoagula-
tion (heparin dosage, level of ACT) and anti-fibrinolytic
(aprotinin) strategies [11,23]. Aggressive transfusion of
platelets is required after termination of cardiopulmonary
bypass—if used—before chest closure. If bleeding mani-
fests on the intensive care, transfusion of platelets should not
be delayed, independently of the platelet count.
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Appendix A. Conference discussion
Dr Y. Balbaa (Cairo, Egypt): I would like to ask you, first, in this group
of patients, did you use aprotinin or not?
Dr Englberger: All patients received at least 2 million units in the pump
prime dose, and it was the decision of the surgeon if he wants to use the high
dose protocol. The high dose protocol was more often used in the
clopidogrel patient group, but despite this, we still had higher bleeding.
Dr Balbaa: My second question is, although the mean drainage for
every patient was about 1.5 l, you had only a percentage of reoperation
about 6%. So what is your limits for taking back the patient to the operating
room?
Dr Englberger: That was an observational study. We did not have really
sharp limits of the chest drainage volume when we take the patients back,
and if you look at the two other trials already published about this problem,
sometimes the chest drainage will exceed more than 2 l within 24 h, but
there is no take back to the OR.
If we expect that it is more a hemostatic derangement in the patients and
not a surgical bleeding, then we really try—and you may know this also
from your hospital—to correct the hemostatic competence of the patient
first. During this time the drainage volume maybe will exceed more than
1.5 l.
Dr Balbaa: And you can leave a patient draining 2 l without taking him
back to the OR?
Dr Englberger: I have seen such patients, yes. I think that is possible.
Dr P. Mortensen (Odense, Denmark): I am very pleased to see that you
didn’t use the surgeons as a risk factor for bleeding. Thank you for that.
What do you think about using epsilon–aminocaproic acid, it is called
Cyklokapron in our country, instead of aprotinin? It is cheaper.
L. Englberger et al. / European Journal of Cardio-thoracic Surgery 26 (2004) 96–101100
Dr Englberger: We do not use these agents very often in our hospital.
We are using always aprotinin, and we do not combine aprotinin with other
antifibrinolytics. In this respect, I cannot answer your question.
But I know that up to now, no single clinical trial is available looking at
the effect of aprotinin on patients who are treated with clopidogrel, and
there is also no trial available looking at the synthetic antifibrinolytics. It is
still a pure empirical decision to use these agents in this situation. But I
think they will work.
Mr K. Rammohan (Cardiff, UK): It is very interesting because there is a
huge percentage of inpatient referrals at the moment, and we face the same
problem. The last slide alluded to the fact that your entire group is people
who are on clopidogrel in the last three days. Am I correct in understanding
that?
Dr Englberger: Yes.
Mr Rammohan: So people whose clopidogrel was stopped before that
are completely excluded from what you mentioned. Is that a logical
conclusion?
Dr Englberger: The patients who stopped clopidogrel three days prior
to surgery are in the control group.
Mr Rammohan: And with the group that you have taken, and you again
mentioned that there may have been an increased ACT, was it consistent
that the clotting was deranged going into theater with all these people?
Dr Englberger: In some patients the ACT level is elevated when they
come in. IV heparin use was the same in both patient groups, but in some
patients you can see that the ACT is elevated if they are on multiple
antiplatelets and/or also on heparin treatment. The recommendation I gave
in the last slide was only in order to say that it is in our eyes not safe to
reduce the intraoperative heparin dose due to an elevated ACT level at the
beginning of surgery. This is often under discussion.
Mr P. Totaro (Swansea, UK): Why did you operate on patients who
were still on clopidogrel or it was not stopped more than three days before?
Were they all unstable patients?
Dr Englberger: The reasons to operate on them within three days are
different. Patients in the clopidogrel group were more ill than the other
patients. I have shown this. But we are also of the opinion that if you plan
elective surgery, it is not strictly necessary to send the patients home if they
are on clopidogrel. If we discussed this in the States where another legal
surrounding exists, maybe we have to question this again. We are of the
opinion surgery can be performed safely with a slightly elevated risk of
bleeding in these patients.
Mr R. Ascione (Bristol, UK): I really would like to congratulate you on
taking to our attention this important topic. We have paid a lot of attention
to this too, and I would like to bring to this audience’s attention our
experience.
We have as a part of our internal clinical audit project done a study over
a year, because we saw that we had an increasing number of referrals of
urgent in-hospital patients with acute coronary syndrome coming through
on a combination of clopidogrel plus aspirin and others. We divided all
those urgent patients according to the preoperative antiplatelet/anticoagula-
tion regimen into four groups. One group had all drugs stopped 5 days
before surgery, because in the meantime they were stabilized; the other
three groups had antiplatelet/anticoagulant drugs within 5 days prior
surgery and they included: a group having aspirin alone, a group on
clopidogrel either alone or plus aspirin, and a group having aspirin with IV
heparin.
We carried out a risk-adjusted analysis to take account of all potential
confounding variables including TIMI risk score.
Our results are pretty much in keeping with yours regarding blood loss
and transfusion requirements. However, the use of clopidogrel either alone
or associated with aspirin was also associated with higher in-hospital
mortality and higher incidence of stroke, and we also had a higher 1-year
mortality in this group.
Our message is that you can safely have clopidogrel up to five days
before surgery, to maintain its benefit of reducing MACE events, but within
5 days prior surgery a more critical approach to these patients is required.
Either one wait a bit longer, if the patient’s clinical condition allows it, or
one should switch them on something else like aspirin and IV heparin.
Dr Englberger: In our study group we did not see a difference in
outcome. Maybe that has to be checked in a larger patient group. Otherwise
your comment is in accordance to that I presented.
L. Englberger et al. / European Journal of Cardio-thoracic Surgery 26 (2004) 96–101 101
